BlackRock, Inc. ownership in KUR / Kura Oncology, Inc.

쿠라 온콜로지, Inc.

DE ˙ DB ˙ US50127T1097

€7.56 ↑0.24 (3.28%)

2026-06-05
주가

Security	DE:KUR / Kura Oncology, Inc.
Institution	BlackRock, Inc.
Latest Disclosed Ownership	6,329,050 shares
Ownership	7.80%

2025-04-17 - BlackRock, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,329,050 shares of Kura Oncology, Inc. (DE:KUR). This represents 7.8 percent ownership of the company. In their previous filing dated 2025-01-08 , BlackRock, Inc. had reported owning 7,934,104 shares, indicating a decrease of -20.23 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2025-04-17	2025-04-17	13G/A	7,934,104	6,329,050	-20.23	7.80	-23.53
2025-01-08	2025-01-08	13G	7,315,647	7,934,104	8.45	10.20	4.08
2024-01-24	2024-01-24	13G/A	5,162,836	7,315,647	41.70	9.80	28.95
2023-01-31	2023-01-31	13G/A	5,095,026	5,162,836	1.33	7.60	-1.30
2022-02-03	2022-02-03	13G/A	4,931,956	5,095,026	3.31	7.70	1.32
2021-01-29	2021-01-29	13G/A	2,993,752	4,931,956	64.74	7.60	15.15
2020-02-05	2020-02-05	13G/A	2,409,979	2,993,752	24.22	6.60	4.76
2019-02-08	2019-02-08	13G	2,409,979	2,409,979	0.00	6.30	0.00
2019-02-07	2019-02-07	13G	1,477,273	2,409,979	63.14	6.30	43.18
2018-03-08	2018-03-08	13G/A	1,524,817	1,477,273	-3.12	4.40	-12.00
2018-02-01	2018-02-01	13G		1,524,817		5.00

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-13	2026-03-31	13F	KURA ONCOLOGY	COM	50127T109	9,637,531	626,738	6.96	78,353	-16.31	0.0001
2026-02-12	2025-12-31	13F	KURA ONCOLOGY	COM	50127T109	9,010,793	-504,342	-5.30	93,622	11.18	0.0016
2025-11-12	2025-09-30	13F	KURA ONCOLOGY	COM	50127T109	9,515,135	44,802	0.47	84,209	54.11	0.0015
2025-08-12	2025-06-30	13F	KURA ONCOLOGY	COM	50127T109	9,470,333	1,292,687	15.81	54,644	1.24	0.0010
2025-05-02	2025-03-31	13F	KURA ONCOLOGY	COM	50127T109	8,177,646	243,542	3.07	53,972	-21.90	0.0011
2025-02-07	2024-12-31	13F	KURA ONCOLOGY	COM	50127T109	7,934,104	778,687	10.88	69,106	-50.57	0.0014
2024-11-13	2024-09-30	13F	KURA ONCOLOGY	COM	50127T109	7,155,417	189,611	2.72	139,817	-2.52	0.0029
2024-08-13	2024-06-30	13F	KURA ONCOLOGY	COM	50127T109	6,965,806	66,437	0.96	143,426	-2.54	0.0032
2024-05-10	2024-03-31	13F	KURA ONCOLOGY	COM	50127T109	6,899,369	-416,278	-5.69	147,164	39.89	0.0034
2024-02-13	2023-12-31	13F	KURA ONCOLOGY	COM	50127T109	7,315,647	394,602	5.70	105,199	66.67	0.0027
2023-11-13	2023-09-30	13F	KURA ONCOLOGY	COM	50127T109	6,921,045	763,643	12.40	63,120	-3.11	0.0018
2023-08-11	2023-06-30	13F	KURA ONCOLOGY	COM	50127T109	6,157,402	788,095	14.68	65,145	-0.79	0.0018
2023-05-12	2023-03-31	13F	KURA ONCOLOGY	COM	50127T109	5,369,307	206,471	4.00	65,667	2.49	0.0019
2023-02-13	2022-12-31	13F	KURA ONCOLOGY	COM	50127T109	5,162,836	283,528	5.81	64,071	-3.87	0.0020
2022-11-14	2022-09-30	13F	KURA ONCOLOGY	COM	50127T109	4,879,308	-82,781	-1.67	66,650	-26.72	0.0023
2022-08-12	2022-06-30	13F	KURA ONCOLOGY	COM	50127T109	4,962,089	14,744	0.30	90,957	14.33	0.0029
2022-05-12	2022-03-31	13F	KURA ONCOLOGY	COM	50127T109	4,947,345	-147,681	-2.90	79,554	11.53	0.0021
2022-02-10	2021-12-31	13F	KURA ONCOLOGY	COM	50127T109	5,095,026	93,610	1.87	71,330	-23.86	0.0018
2021-11-09	2021-09-30	13F	KURA ONCOLOGY	COM	50127T109	5,001,416	39,035	0.79	93,678	-9.46	0.0026
2021-08-11	2021-06-30	13F	KURA ONCOLOGY	COM	50127T109	4,962,381	-261,165	-5.00	103,466	-29.93	0.0029
2021-05-07	2021-03-31	13F	KURA ONCOLOGY	COM	50127T109	5,223,546	291,590	5.91	147,669	-8.33	0.0043
2021-02-05	2020-12-31	13F	KURA ONCOLOGY	COM	50127T109	4,931,956	547,852	12.50	161,079	19.91	0.0051
2020-11-06	2020-09-30	13F	KURA ONCOLOGY	COM	50127T109	4,384,104	46,592	1.07	134,329	90.00	0.0050
2020-08-14	2020-06-30	13F	KURA ONCOLOGY	COM	50127T109	4,337,512	1,389,746	47.15	70,701	141.06	0.0028
2020-05-01	2020-03-31	13F	KURA ONCOLOGY	COM	50127T109	2,947,766	-45,986	-1.54	29,329	-28.75	0.0014
2020-02-13	2019-12-31	13F	KURA ONCOLOGY	COM	50127T109	2,993,752	21,563	0.73	41,164	-8.70	0.0016
2019-11-08	2019-09-30	13F	KURA ONCOLOGY	COM	50127T109	2,972,189	565,151	23.48	45,088	-4.87	0.0019
2019-08-22	2019-06-30	13F/A-1	KURA ONCOLOGY	COM	50127T109	2,407,038	61,255	2.61	47,396	21.78	0.0020
2019-08-13	2019-06-30	13F	KURA ONCOLOGY	COM	50127T109	2,407,038	61,255		47,396
2019-05-09	2019-03-31	13F	KURA ONCOLOGY	COM	50127T109	2,345,783	-64,196	-2.66	38,918	15.02	0.0017
2019-02-08	2018-12-31	13F	KURA ONCOLOGY	COM	50127T109	2,409,979	13,842	0.58	33,836	-19.31	0.0017
2018-11-09	2018-09-30	13F	KURA ONCOLOGY	COM	50127T109	2,396,137	393,872	19.67	41,932	15.07	0.0018
2018-08-09	2018-06-30	13F	KURA ONCOLOGY	COM	50127T109	2,002,265	406,963	25.51	36,440	21.83	0.0017
2018-05-09	2018-03-31	13F	KURA ONCOLOGY	COM	50127T109	1,595,302	70,485	4.62	29,910	28.20	0.0014
2018-02-09	2017-12-31	13F	KURA ONCOLOGY	COM	50127T109	1,524,817	502,296	49.12	23,331	52.62	0.0011
2017-11-14	2017-09-30	13F	KURA ONCOLOGY	COM	50127T109	1,022,521	427,626	71.88	15,287	176.34	0.0008
2017-08-10	2017-06-30	13F	KURA ONCOLOGY	COM	50127T109	594,895	555,938	1,427.06	5,532	1,512.83	0.0003
2017-05-12	2017-03-31	13F	KURA ONCOLOGY	COM	50127T109	38,957	38,957		343		0.0000

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.